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http://dxBackground: The objective of this collaborative, multicenter, European effort was to evaluate the outcomes of
the convergent procedure for the treatment of persistent and long-standing persistent atrial fibrillation (AF) in
consecutive patients at 4 European centers.
Methods: Outcomes of consecutive patients, undergoing the convergent procedure at 4 European centers, were
evaluated in this study. Epicardial ablation was performed before endocardial ablation. Convergent procedure
outcomes were recorded by interrogation of implanted loop recorders or Holter monitors. Rhythm status and
required interventions (antiarrhythmic drugs, cardioversions, and repeat ablations) were quantified 6 and 12
months after the procedure. Outcomes, monitoring type, and patient baseline characteristics were analyzed
and reported.
Results: Seventy-three consecutive patients presenting with persistent AF (30.1%) or long-standing persistent
AF (69.9%) underwent the convergent procedure between January 2010 and December 2011. At 6 months, 82%
(56/68) were in sinus rhythm. At 12 months, 80% (53/66) were in sinus rhythm; single-procedure maintenance
of sinus rhythm without postblanking period interventions was 76% (50/66); 52% (34/66) were in sinus rhythm
and not receiving antiarrhythmic drugs.
Conclusions: This multicenter European collaborative effort demonstrated that the convergent procedure is a
safe and efficacious treatment option for persistent and long-standing persistent AF. (J Thorac Cardiovasc
Surg 2014;147:1411-6)Atrial fibrillation (AF) treatment needs new modalities to
treat the most prevalent and complex forms of AF, persistent
and long-standing persistent. Catheter ablation has become
a primary treatment modality for drug refractory, symptom-
atic paroxysmal AF, but has demonstrated limited efficacy
in persistent and long-standing persistent AF. The 5-year
arrhythmia-free survival for a single catheter ablation
procedure in a predominantly paroxysmal patient popula-
tion has been reported at 29%, whereas the efficacy
after multiple procedures was 63%.1 Consequently, the
incidence and recurrence of AF greatly exceed the number
of patients successfully treated, causing explosive growth
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SIsolation of focal triggers associated with the pulmonary
veins (PVs) is a cornerstone of any AF treatment strategy.3,4
However, simple PV isolation does not address reentrant
circuits associated with persistent and long-standing
persistent AF or patients with structural heart disease and
enlarged atria.5 The posterior left atrium has become a
target of interest in patients having chronic atrial stretch
and AF because of observations of conduction abnorma-
lities, including slower conduction, heterogeneity, and
numerous lines of functional block.6 Therefore, to treat
the most prevalent complex forms of AF, an effective
procedure must isolate the PVs and the posterior left atrium
without hindering heart function or the ability of the heart to
reverse remodel once sinus rhythm is restored.
The convergent procedure was developed to directly
access and visualize the posterior left atrium to isolate
the PVs and ablate the posterior left atrium while
offering minimal surgical trauma combined with precision
of the electrophysiologic 3-dimensional mapping. The
multidisciplinary approach leverages the ability of the
endoscopic surgeon to complete lines of conduction block
with the electrophysiologist’s ability to map the lines of
block, identify breakthroughs, and complete isolation of
the PVs. By combining these 2 disciplines, a comprehensive
pattern of endocardial and epicardial lesions is created
without chest incisions, lung deflation, or invasive heartdiovascular Surgery c Volume 147, Number 4 1411
Abbreviations and Acronyms
AF ¼ atrial fibrillation
PV ¼ pulmonary vein
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Sdissections. The purpose of this article is to evaluate
outcomes of the multidisciplinary closed chest convergent
procedure for the treatment of persistent and long-
standing persistent AF.METHODS
This is an outcomes data evaluation study performed at 4 European
centers in compliance with the Declaration of Helsinki. Local medical
ethics committee approval was obtained by each site before study
initiation. All patients with a history of persistent or long-standing
persistent AF consenting to study participation were eligible for inclusion
in the study. Seventy-three patients consented; consecutive AF patients
underwent the convergent procedure at the 4 centers between January
2010 and December 2011. A 3-month blanking period was allowed; any
AF treatments within this period were not considered efficacy failures,
except any endocardial catheter ablations were recorded as redos.
Multidisciplinary AF Treatment
The epicardial and endocardial ablation components of the convergent pro-
cedure were performed as a single-setting procedure on the same day or as a
staged procedure, with the epicardial and endocardial components performed
on 2 different days, as 2 different hospitalizations. At one center, all the proce-
dureswereperformedas stagedproceduresminimally2weeks apart to accom-
modate local reimbursement challenges. At a second center, 50% of the
procedures were performed as staged procedures minimally 2 months apart.
Transdiaphragmatic Access and Epicardial Ablation
Endoscopic access to posterior cardiac structureswas established through
3 small abdominal stab incisions. Low-pressure insufflation of the belly
provided visualization of the central tendon portion of the diaphragm.
Epicardial access was first obtained by creating a pericardial window with
a shielded Teflonmonopolar electrocautery hook probe (ATCTechnologies,
Wilmington,Mass) through the visualized central tendon of the diaphragm.7
A transdiaphragmatic window to the pericardium allowed introduction of a
soft shallow angle cannula (nContact, Inc, Morrisville, NC) into a retrocar-
diac position, giving a direct view of the posterior left atrium and allowing
manipulation of the cannula without compromising hemodynamics. After
accessing the left atrium, linear epicardial lesions were created along the
posterior region of the left atrium.8 At all 4 sites, preset power (30 W) and
time (90 seconds) settings for the Numeris Guided Coagulation System
(nContact, Inc) were used for the creation of each epicardial lesion.
Figure 1, A, shows the base lesion pattern. Posterior left atrial lesions
were created between the left and right pulmonary veins within the oblique
sinus that is outlined by the pericardial reflections. After ablating the
posterior left atrium between the left and right pulmonary veins, linear
lesions were created anterior to the left pulmonary veins toward the
ligament of Marshall. Finally, lesions were created anterior to the right
pulmonary veins and inferior vena cava parallel to the interatrial groove.
After the creation of all epicardial lesions, the abdominal access sites
were closed and the patient was prepared for standard left-sided endocar-
dial ablation for the convergent procedures performed in a single setting.
Epicardial Ablation System
The Numeris Guided Coagulation System, designed for such closed-
chest, thoracoscopic procedures, was used for the endoscopic visualization1412 The Journal of Thoracic and Cardiovascular Surof the pericardial space and the creation of epicardial linear lesions. The
epicardial ablation device and cannula used to access the pericardial space
are shown in Figure 1, B and C.
Suction applied to the helical coil electrode ensures consistent and pre-
dictable contact with cardiac tissue during radio frequency ablation. A
perfusion lumen coupled to the vacuum lumen is routed to an unpressurized
bag of saline. Once a vacuum seal is obtained, saline is pulled along the de-
vice, cooling the surface of the instrument not in contactwith the epicardium
and focusing RF energy into the epicardium. This ensures a complete lesion
that extends to the endocardium. The vacuum-controlled saline perfusion
also provides a visible indicator that a vacuum seal has been maintained.
The design of the device solves the critical requirements for the creation
of complete, nonconductive lesions capable of interrupting erratic
electrical signals, as demonstrated by chronic good clinical practice pre-
clinical studies.9 The lesions are visible along the epicardial surface of
the heart, allowing them to be easily connected under direct visualization
into a pattern capable of interrupting and silencing deviant circuits. The
radiofrequency generator uses an algorithm based on impedance that
regulates power to prevent tissue overheating and subsequent vaporization.
The Numeris system has received the Conformite Europeenne mark of
approval for the coagulation of cardiac tissue using radiofrequency energy
for the treatment of arrhythmias, including atrial fibrillation or atrial flutter.
Transseptal Access and Endocardial Catheter
Ablation
Percutaneous venous catheterization was used to introduce catheters into
the right atrium. A coronary sinus catheter was inserted to provide a reference
for 3Dnavigation.A transseptal puncturewasused to access the left atriumand
introduce mapping and ablation catheters. Electrophysiologist mapping tech-
niques, including interrogation of intracardiac electrograms with a Lasso cath-
eter or voltage mapping with Carto3 (Biosense Webster, Diamond Bar, Calif)
or NavX (St Jude Medical, St Paul, Minn), were performed to identify break-
throughs between epicardial lesions along the pericardial reflections. Endocar-
dial lesions were created to connect the epicardial lesions and complete the
pulmonary vein isolation. Each site used the endocardial catheter andmapping
systems of its choice. In Slovenia, Celsius catheters were used without a nav-
igation system, andwithpower set at25 to30Wandan irrigation rate of 60mL/
min when ablating and 2 mL/min when on standby. In Germany, Thermocool
catheters (Biosense Webster) were used with either Carto or NavX mapping
systems; endocardial ablation was performed at 20 to 30 W with an irrigation
rate of 17mL/min. In France, theBiosenseNavistar irrigated catheterwas used
with theCartomapping system;during endocardialRFablation, power settings
of26 to35Wwereused,with42Casa target temperature andan irrigation rate
of 17 and 22 mL/min. In Poland, the NaviStar catheter system (Biosense
Webster) was usedwith the Carto 3-dimensionalmapping system; endocardial
ablation was performed with a power setting of 40 W for 60 seconds.
All sites performed entrance and/or exit block testing to ensure
electrical isolation of the PVs and the posterior atria.
Postoperative Management
Antiarrhythmic drug therapy was directed by the referring physician
throughout follow-up. Anticoagulation was reinitiated postoperatively
and continued for at least 3 months, and was also directed by the referring
physician. Postoperative pain management was at each physician’s discre-
tion. Level of pain was a subjective patient response from low to moderate
levels. Hospital stay averaged 5 days for patients undergoing the convergent
procedure in a single setting and the epicardial ablation procedure in the
staged procedure setting. Hospital stay averaged 2 days for patients under-
going the endocardial ablation procedure in the staged procedure setting.
Follow-up Monitoring
A total of 65% (48/73) of patients were implanted with
implantable loop recorders (Reveal XT Insertable Cardiac Monitors;gery c April 2014
FIGURE 1. A, Base lesion pattern. B, Epicardial coagulation device with cannula. C, Cross-section and close-up of the epicardial coagulation device
electrode. SVC, Superior vena cava; RA, right atrium; IVC, inferior vena cava; LA, left atrium; LPV, left pulmonary vein; PA, pulmonary artery; RF, radio
frequency.
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SMedtronic, Inc, Minneapolis, Minn). Holter monitoring (24 hours or
7 days) was performed on the remaining patients. Rhythm data were
interrogated at regular follow-up intervals (3, 6, and 12 months).
Patients were further evaluated with transthoracic echocardiography
at 6- and 12-month follow-up visits. Follow-up time points were
calculated after the completion of both epicardial and endocardial
components of the convergent procedure when performed as a staged
procedure.
Follow-up data of 6 months or greater were recorded for 68 patients;
of these patients, 66 had 12-month follow-upmonitoring data. Two patients
who were converted to sternotomies and received epicardial ablation
only were excluded from the efficacy analysis.The Journal of Thoracic and CarStatistical Analysis
Baseline and follow-up values are reported as mean  SD for numeric
measures and counts and percentages for categorical measures. Kaplan-
Meier survival analysis was performed for the total patient population.
For comparison of left atrial size and left ventricular ejection fraction,
paired t-tests were performed, with means and SDs reported only for sub-
sets in which data were available at both baseline and 12-month follow-up.
RESULTS
Seventy-three consecutive patients receiving the conver-
gent procedure were included in the baseline demographicdiovascular Surgery c Volume 147, Number 4 1413
TABLE 2. Serious adverse event rates
Serious adverse event No. (%) of 73
Operative mortality 0 (0)
<30-d Mortality 0 (0)
>30-d Mortality 0 (0)
Stroke/CVA 1 (1.4)
TIA 0 (0)
Tamponade 1 (1.4)
Pericardial effusion 1 (1.4)
Pleural effusion 1 (1.4)
Phrenic nerve palsy 0 (0)
Esophageal fistula 0 (0)
Myocardial infarction 0 (0)
Newly developed third-degree AV block 0 (0)
Acute limb ischemia 0 (0)
Bleeding requiring transfusion 2 (2.7)
Bleeding with conversion to sternotomy 2 (2.7)
Serious adverse events were observed in 8 patients (8 of 73; 11%). CVA, Cerebrovas-
cular accident; TIA, transient ischemic attack; AV, atrioventricular.
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persistent, with an average AF duration of 4.3  4.4 years,
as defined by the Heart Rhythm Society recommenda-
tions.10 Baseline demographics are detailed in Table 1.
The mean patient age was 56.3 years, and 81% were
male. The mean baseline left atrial size and left ventricular
ejection fraction were 46.5 mm and 54.7%, respectively,
based on transthoracic echocardiographic measurements.
The skin-to-skin epicardial procedure time was 111.6 
38.4 minutes. An average of 19 epicardial lesions were
created for each patient, with an epicardial RF ablation
time of 22.7  7.9 minutes.
Serious adverse event rates are listed in Table 2. There
was no operative, perioperative, or late mortality. One
cerebral vascular incident was observed. Two patients had
bleeding that required conversion to sternotomies. Two
more patients had abdominal bleeding that required blood
transfusion without intervention.
Efficacy outcomes are detailed in Table 3. A total of
82% of patients were in sinus rhythm at 6-month
follow-up; 76% were in sinus rhythm without repeat
ablation procedures or interventions outside the blanking
period. A total of 80% of patients were in sinus rhythm at
12 months; 76% had a single-procedure efficacy without
subsequent interventions, and 52% were in sinus rhythmTABLE 1. Demographic characteristics
Characteristic All subjects (n ¼ 73)
Male, No. (%) 59 (81)
Age, y
Mean (SD) 56.3 (10.5)
Range 28-75
BMI, kg/m2
Mean (SD) 29.4 (4.7)
Range 20.2-49.1
Preoperative LA, mm
Mean (SD) 46.5 (5.5)
Range 28-57
Preoperative LVEF,%
Mean (SD) 54.7 (12.2)
Range 20-80
Atrial fibrillation type, No. (%)
Persistent 22 (30)
Long-standing persistent 51 (70)
AF duration, y
Mean (SD) 4.3 (4.4)
Range 0.5-25
Preexisting conditions, No. (%)
Congestive heart failure 16 (22)
Hypertension 50 (68)
Diabetes 9 (12)
Stroke/TIA/thromboembolic event 5 (7)
Vascular disease (CAD, PAD) 5 (7)
BMI, Body mass index; LA, left atrium; LVEF, left ventricular ejection fraction;
AF, atrial fibrillation; TIA, transient ischemic attack; CAD, coronary artery disease;
PAD, peripheral arterial disease; SD, standard deviation.
1414 The Journal of Thoracic and Cardiovascular Surand not taking antiarrhythmic drugs. The 2 patients who
were converted to sternotomies and received epicardial
ablation only (not included in efficacy analysis) were in
SR at 6 months, with 1 of the 2 patients reverting to AF at
12 months.
Figure 2 shows an arrhythmia- and intervention-free
survival analysis throughout 1 year of follow-up. The
cumulative survival in terms of lack of arrhythmia
recurrence and interventions throughout 1-year follow-up
was 73%. Only 3 patients (4%) required repeat ablation
procedures.
Left atrial size decreased throughout follow-up, from an
average of 46.5  5.5 mm at baseline to 42.9  6.2 mm at
12 months (P < .01). Left ventricular ejection fraction
increased throughout follow-up, from an average of
54.7%  12.2% at baseline to 58.5%  12.6% at 12
months (P<.01).DISCUSSION
Stand-alone surgical and catheter ablation approaches
have been limited in the ability to effectively ablate
the posterior left atrium or create linear lesions capable
of interrupting macro-reentrant circuits. The original
cut-and-sew Maze III procedure used a highly invasive,TABLE 3. Outcomes at each follow-up visit
Clinical measure/follow-up % (No./total) responders
Sinus rhythm
6 mo 82 (56/68)
12 mo 80 (53/66)
Sinus rhythm, no interventions
6 mo 76 (52/68)
12 mo 76 (50/66)
gery c April 2014
FIGURE 2. Arrhythmia and intervention-free survival analysis.
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posterior left atrium, along with other lines throughout the
right and left atria.11
Literature suggests the posterior left atrium, bounded by
the pericardial reflections and extending between the left
and right pulmonary veins, derives embryologically from
pulmonary vein tissue and produces lines of functional
conduction block that may exacerbate the potential for
developing arrhythmogenic substrates.6 Access to and
visualization of the posterior left atrium may be essential
to localize ablation along the target posterior left atria that
is tethered by the pericardial reflections.
The convergent procedure combines 2 important medical
disciplines for the treatment of persistent and long-standing
persistent AF. Laparoscopic epicardial creation of linear
lesions is augmented by endocardial catheter ablation along
the pericardial reflections; endocardial mapping further
ensures pulmonary vein isolation is obtained and the lesion
pattern is complete.
This multicenter evaluation of the convergent procedure
demonstrated the ability to restore sinus rhythm in
persistent and long-standing persistent AF patients and
avoid dependence on continued interventions, including
cardioversions or repeat catheter ablation procedures.
Discontinuation of antiarrhythmic drug therapy is affected
by patient choice, physician discretion, and the need for
drugs to address other concomitant medical conditions.
Despite treating a more difficult AF patient population,
the outcomes compare favorably to those published for
catheter ablation of paroxysmal AF.12,13
Catheter ablation studies have observed a continued
decrease in outcomes more than 1 year after AF ablation
and require a high redo rate to achieve outcomes greater
than 50%.1,4,14 In addition, surgical studies have
demonstrated a substantial reduction in outcomes whenThe Journal of Thoracic and Caraccess limitations inhibit the ability to isolate the
posterior left atrium, even when using limited monitoring
methods, such as electrocardiograms.15
Stand-alone surgical ablation approaches to treat atrial
fibrillation have been limited by the morbidity associated
with surgical access requiring chest incisions or ports.
Based on the Society of Thoracic Surgeons Database,
major complications for stand-alone surgical AF ablation
occurred in 27.97% of on-pump and 13.60% of off-
pump patients, with an operative mortality of 1.7% and
0.5%, respectively.16 In addition, the high readmission
rates (11%) highlight the invasiveness of on- and off-
pump surgical ablation approaches, which will continue
to limit widespread adoption compared with catheter
ablation.
In comparing catheter ablation with surgical ablation, the
FAST randomized study reported 12-month postprocedure
freedom from AF of 65.6% for surgical ablation and
36.5% for catheter ablation. However, the procedural
adverse events were much higher in the surgical ablation
arm, although a comparable number of serious adverse
events were reported in both arms during the 12-month
follow-up.17
The convergent procedure avoids chest incisions and
single-lung ventilation to reduce complications associated
with surgical ablation while creating a comprehensive
lesion pattern not easily attained with catheter ablation
alone. This multicenter evaluation confirmed the ability
to create linear lesions along the posterior left atrium
to generate an efficacy of 80% of patients in SR at
12 months postprocedure, with an adverse event rate of
11%.
The ability to access the posterior left atrium through a
closed-chest epicardial approach enables creation of
epicardial lesions under direct visualization. The lesion
pattern in the current study did not include isolating the
entire posterior left atrium but involved connecting the
left to right pulmonary veins in the posterior left atrium
parallel to the pericardial reflections. Alternative lesion
patterns that isolate the posterior left atrium may be
evaluated to compare long-term outcomes. However, heart
function must be preserved for any minimally invasive
procedure to succeed.
In this evaluation, left atrial size decreased 7% from
baseline, whereas the left ventricular ejection fraction
increased 5% over baseline. These changes are only
attributed to the convergent procedure because they were
stand-alone treatments of AF. Although not direct measures
of atrial contractility, they do represent qualitative improve-
ment in heart function and reverse remodeling.
The success of this completely closed-chest, combined
approach in treating persistent and long-standing persistent
patients may result from the ability to ablate epicardial
substrates, create a comprehensive pattern of continuousdiovascular Surgery c Volume 147, Number 4 1415
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atrium, create a cavotricuspid isthmus lesion, and ensure
lesion completeness using endocardial mapping and
ablation.
The ability to evaluate epicardial lesion integrity
addresses the primary technology limitation of all
epicardial ablation devices, which are less effective
when ablating over fat. By mapping epicardial lesion
completeness during the electrophysiologic portion of
the procedure, gaps between or along epicardial lesions
may be identified and ablated endocardially. In addition,
electrophysiologic testing of pulmonary vein isolation
and inducibility of atrial arrhythmias provide more
definitive metrics of procedure completeness. However,
the procedure still depends on catheter ablation tech-
niques, with their documented limitations in creating
transmural lesions.
This study was limited by the variability in the timing
of the treatment protocol between epicardial and endocar-
dial procedures. Most procedures were performed in a
single setting, but because the cohort of patients involved
consecutive enrollment, differences between procedure
timing and techniques of both epicardial and endocardial
ablation may limit poolability for comparative purposes.
The promise of leveraging the positives of 2 medical
specialties (cardiac surgery and electrophysiology) has
generated interest and is being evaluated for the treatment
of persistent and long-standing AF. Multiple hybrid
procedures are being evaluated at centers around the world,
with varying efficacy and safety results using various
epicardial ablation technologies and varying methods to
achieve access to the posterior of the heart.8,15,18
Procedures are performed as a single procedure on the
same day or are staged with a varied time interval
between the epicardial ablation and the endocardial
ablation. Access to the heart is obtained through bilateral
thoracotomies, minithoracotomies, requiring lung deflation
and dissection of the attachments between the pericardium
and atria. Randomized, controlled, multicenter studies
need to be conducted with a standardized lesion pattern
and monitoring method with a standardized definition of
treatment success.
Outcomes from this 4 European centers’ data analysis
indicate that the convergent procedure provides a
viable treatment option for persistent and long-standing
persistent AF patients. Larger studies, potentially controlled
and randomized, with a standardized treatment protocol,
are needed to definitively establish the impact of this1416 The Journal of Thoracic and Cardiovascular Surconvergent procedure on heart function, cost-effectiveness,
and long-term survival.
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